.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

ABSORICA Drug Profile

« Back to Dashboard
Absorica is a drug marketed by Ranbaxy and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and three Paragraph IV challenges.

This drug has ten patent family members in eight countries.

The generic ingredient in ABSORICA is isotretinoin. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.

Summary for Tradename: ABSORICA

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: ABSORICA

Ingredient-typeRetinoids
Drug ClassRetinoid
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-004May 25, 2012RXYes8,952,064► subscribeY ► subscribe
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-004May 25, 2012RXYes7,435,427► subscribeY ► subscribe
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-001May 25, 2012RXNo8,367,102► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ABSORICA

Drugname Dosage Strength RLD Submissiondate
isotretinoinCapsules30 mg and 40 mgAbsorica12/31/2012
isotretinoinCapsules20 mgAbsorica6/19/2013
isotretinoinCapsules20 mgAbsorica1/7/2013

International Patent Family for Tradename: ABSORICA

Country Document Number Estimated Expiration
Portugal1318791► subscribe
World Intellectual Property Organization (WIPO)2015094574► subscribe
Australia8943801► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc